Evidence map›Paper›PMID 37263492›Full record

ArticleContemporary clinical trials2023

Design, implementation and preliminary results of a type-2 hybrid cluster-randomized trial of integrating screening and treatment for major depressive disorder into specialty clinics providing opioid agonist therapies in Ukraine.

Eteri Machavariani, Daniel J Bromberg, Kostyantyn Dumchev, Sergii Dvoriak, Oleksandr Zeziulin, Olga Morozova, Denise Esserman, Iryna Pykalo, Nataliia Saichuk, Roman Ivasiy and 2 more

Open access · greenAbstract readClinical Trial Protocol
In one paragraph

Article in Contemporary clinical trials, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 2 countries.

Eteri MachavarianiSection of Infectious Diseases, Yale School of Medicine, New Haven, CT, United States. Electronic address: eteri.machavariani@yale.edu.
Daniel J BrombergCenter for Interdisciplinary Research on AIDS, Yale University, New Haven, CT, United States; Department of Social and Behavioral Sciences, Yale School of Public Health, Yale University, New Haven, CT, United States.
Kostyantyn DumchevUkrainian Institute on Public Health Policy, Kyiv, Ukraine.
Sergii DvoriakUkrainian Institute on Public Health Policy, Kyiv, Ukraine.
Oleksandr ZeziulinUkrainian Institute on Public Health Policy, Kyiv, Ukraine.
Olga MorozovaDepartment of Public Health Sciences, University of Chicago, Chicago, IL, United States.
Denise EssermanDepartment of Biostatistics, Yale School of Public Health, Yale University, New Haven, CT, United States.
Iryna PykaloUkrainian Institute on Public Health Policy, Kyiv, Ukraine.
Nataliia SaichukUkrainian Institute on Public Health Policy, Kyiv, Ukraine.
Roman IvasiySection of Infectious Diseases, Yale School of Medicine, New Haven, CT, United States.
Marwan S HaddadCenter for Key Populations, Community Health Center Inc, Middletown, CT, United States.
Frederick L AlticeSection of Infectious Diseases, Yale School of Medicine, New Haven, CT, United States; Center for Interdisciplinary Research on AIDS, Yale University, New Haven, CT, United States; Division of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, United States.
Ukrainian Institute of Public Health Policy · UAYale University · USChicago Department of Public Health · USCommunity Health Center · US

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Expanding Medication Assisted Therapy in Ukraine (ExMAT)R01DA033679 · NIDA · YALE UNIVERSITY · PI ALTICE, FREDERICK LEWIS · 2012 to 2021
$6.4M
Integrating Addiction Treatment and HIV Services into Primary Care Clinics in UkraineR01DA043125 · NIDA · YALE UNIVERSITY · PI ALTICE, FREDERICK LEWIS · 2016 to 2021
$4.4M
Integrating Treatment for Mental Disorders in Methadone Clinics in UkraineU01DA045384 · NIDA · UKRAINIAN INSTITUTE ON PUBLIC HEALTH POLICY · PI DVORIAK, SERGII · 2018 to 2020
$1.4M
Integrating Treatment for Mental Disorders in Methadone Clinics in UkraineR01DA045384 · NIDA · UKRAINIAN INSTITUTE ON PUBLIC HEALTH POLICY · PI DVORIAK, SERGII · 2021 to 2022
$884k
Developing, Implementing, and Pilot Testing an Informed Decision Aid for Opioid Agonist Therapies for Prisoners in UkraineF31DA054861 · NIDA · YALE UNIVERSITY · PI BROMBERG, DANIEL J · 2021 to 2023
$94k
NCATS NIH HHS UL1 TR001863NIDA NIH HHS F31 DA054861NIDA NIH HHS R01 DA033679NIDA NIH HHS R01 DA043125NIDA NIH HHS R01 DA045384NIDA NIH HHS U01 DA045384
6 · The paper itself

Abstract

introductionUkraine has a high prevalence of co-occurring disorders (COD), defined as having both substance use (SUD) and psychiatric disorders. Major depressive disorder (MDD) is the most prevalent psychiatric disorder among people with SUD. People with COD experience poor health outcomes, and international agencies propose integrated COD care. In Ukraine, treatment for SUD is delivered in specialized substance use clinics, without providing any other medical services for comorbidities, including MDD. Here we present the protocol, along the with the preliminary results of the MEDIUM project, including observations over the first 6 months.

methodsA cluster-randomized type-2 hybrid trial was conducted to integrate MDD treatment into specialty clinics providing opioid agonist therapies (OAT) in Ukraine. Twelve clinics in four regions underwent randomization to control (N = 1) vs experimental arms (N = 2) in each region. Clinicians at experimental sites received tele-education through modified project ECHO using a facilitated screening, evaluation, and treatment algorithm of depression, with or without financial incentives. Service-, patient- and provider-level data were collected for the analysis every 6 months for 24 months. PRELIMINARY

resultsFor service delivery outcomes, 4421 patients enrolled on OAT across all sites were assessed for MDD for screening (76.7%), evaluation with diagnosis (43.5%) and treatment (30.7%) for MDD; 13.8% continued treatment at least for 6 months. For patient-level outcomes, 1345 patients and 54 providers participated in serial surveys every six months.

conclusionThis study will be the first to explore integrated COD care in Ukraine and generate evidence on effective service integration and delivery strategies for people with COD receiving treatment at substance use clinics with broader implications for Eastern Europe and Central Asia region.

Indexed as

Major Depressive DisorderOpioid-Related DisordersSubstance Abuse, IntravenousAnalgesics, OpioidHumansRandomized Controlled Trials as TopicUkraineAnalgesics, OpioidCo-occurring disorders (COD)DepressionImplementation scienceOpioid agonist therapies (OAT)OpioidsPeople who inject drugs (PWID)Ukraine

Identifiers

PMID37263492
PMCPMC10527419
OpenAlexW4378839522

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.